Medicine and Dentistry
Diffuse Alveolar Damage
72%
Mammalian Target of Rapamycin Inhibitor
54%
Mechanistic Target of Rapamycin
45%
Therapeutic Procedure
27%
Tumor Progression
18%
Anticarcinogen
18%
Lung
18%
Pathogenesis
9%
Diseases
9%
Bacterium
9%
Malignant Neoplasm
9%
Cancer Growth
9%
Drug Therapy
9%
Development
9%
Silo-Filler's Disease
9%
Radiological Finding
9%
Lung Injury
9%
Diagnosis
9%
Kidney Metastasis
9%
Lung Complication
9%
Tissue Damage
9%
Association
9%
Analysis
9%
Tissues
9%
T Cell
9%
Cancer Treatment
9%
Nursing and Health Professions
Patient
90%
Mammalian Target of Rapamycin Inhibitor
54%
Mammalian Target of Rapamycin
45%
Anticarcinogen
18%
Inpatient
18%
Tumor Growth
18%
Diseases
9%
Side Effect
9%
Malignant Neoplasm
9%
Lung Disease
9%
Pathogenesis
9%
Diagnosis
9%
Lung Injury
9%
Kidney Metastasis
9%
Analysis
9%
Contrast
9%
Lung Complication
9%
Cancer Growth
9%
Biochemistry, Genetics and Molecular Biology
Mammalian Target of Rapamycin
100%
Pneumocyte
36%
T Cell
18%
Molecule
18%
Growth
18%
Bacterium
9%
Development
9%
Contrast
9%
Association
9%
Pharmacology, Toxicology and Pharmaceutical Science
Mammalian Target of Rapamycin Inhibitor
54%
Mammalian Target of Rapamycin
45%
Anticarcinogen
18%
Tumor Growth
18%
Diseases
9%
Bacterium
9%
Pathogenesis
9%
Cancer Growth
9%
Lung Disease
9%
Malignant Neoplasm
9%
Lung Injury
9%
Kidney Metastasis
9%
Lung Complication
9%
Immunology and Microbiology
Lung
36%
Molecule
18%
Growth
18%
Tissues
18%
Bacterium
9%
Carcinoma Cell
9%
Development
9%
Contrast
9%
Association
9%